Radiometer adds NT-proBNP and Troponin T to its cardiovascular
Radiometer has added assays for NT-proBNP and Troponin T to the panel
of cardiovascular markers that can be assessed at the point of care
using its new AQT90 FLEX POC immunoassay platform. This follows the
company being granted non-exclusive license under patent rights of Roche
The addition of NT-proBNP and Troponin T further extends a portfolio
of tests that already includes Troponin I, CKMB and Myoglobin and allows
users to select the markers they need for the rapid diagnosis of
congestive heart failure (CHF) and acute myocardial infarction (AMI).
The breadth of this panel also means that the AQT90 FLEX can help with
risk stratification in patients with CHF and AMI, for the selection of
more intensive therapy and interventions in patients with elevated
to take up minimum bench space, the AQT90 FLEX (right) provides
laboratory standard results right at the very point of care. Up to 30
blood samples can be analysed per hour, and all the usual steps required
for this type of testing have either been completely removed or
automated. This reduces the risk of errors and cuts the costs associated
with resampling. As the AQT90 FLEX is a closed system, the risk of
operator contact with blood and waste has been totally eliminated.
In addition to measuring cardiovascular markers, the AQT90 FLEX can
also be used to monitor infection, coagulation and pregnancy markers
using a single whole blood sample.
"This agreement with Roche Diagnostics enables Radiometer Medical to
offer a wide portfolio of cardiac tests on our newly launched POC
immunoassay instrument. Combined with our pipeline of other STAT tests,
this puts Radiometer in a very strong position to reach its goal of
becoming a company offering a full STAT testing solution" says Peter
Kürstein, President, Radiometer Medical.
Bookmark this page